Intercept Pharmaceuticals (NAS:ICPT) Shiller PE Ratio

: (As of Today)

View and export this data going back to 2012. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation

Intercept Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Intercept Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Shiller PE Ratio

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Shiller PE Ratio																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Shiller PE Ratio falls in comparison to its industry or sector. The grey bar indicates the Shiller PE Ratio's extreme value range as defined by GuruFocus.

Intercept Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Intercept Pharmaceuticals's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, Intercept Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS	=	Earnings per Share (Diluted)	/	CPI of Mar. 2023 (Change)	*	Current CPI (Mar. 2023)
	=	-0.77	/	127.3478	*	127.3478
	=	-0.770

Current CPI (Mar. 2023) = 127.3478.

Intercept Pharmaceuticals Quarterly Data

	Earnings per Share (Diluted)	CPI	Adj_EPS
201306	-0.790	98.518	-1.021
201309	-1.650	98.790	-2.127
201312	-0.610	98.326	-0.790
201403	-12.610	99.695	-16.108
201406	1.510	100.560	1.912
201409	-1.690	100.428	-2.143
201412	-1.630	99.070	-2.095
201503	-1.780	99.621	-2.275
201506	-1.990	100.684	-2.517
201509	-2.100	100.392	-2.664
201512	-3.620	99.792	-4.620
201603	-5.170	100.470	-6.553
201606	-3.140	101.688	-3.932
201609	-3.590	101.861	-4.488
201612	-4.840	101.863	-6.051
201703	-3.610	102.862	-4.469
201706	-3.460	103.349	-4.263
201709	-2.890	104.136	-3.534
201712	-4.430	104.011	-5.424
201803	-3.220	105.290	-3.895
201806	-2.580	106.317	-3.090
201809	-2.180	106.507	-2.607
201812	-2.970	105.998	-3.568
201903	-3.030	107.251	-3.598
201906	-2.280	108.070	-2.687
201909	-2.590	108.329	-3.045
201912	-2.990	108.420	-3.512
202003	-2.860	108.902	-3.344
202006	-1.920	108.767	-2.248
202009	-2.010	109.815	-2.331
202012	-1.580	109.897	-1.831
202103	-1.220	111.754	-1.390
202106	-0.330	114.631	-0.367
202109	-0.110	115.734	-0.121
202112	-1.230	117.630	-1.332
202203	-0.580	121.301	-0.609
202206	-0.250	125.017	-0.255
202209	7.800	125.227	7.932
202212	-0.500	125.222	-0.508
202303	-0.770	127.348	-0.770

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Intercept Pharmaceuticals (NAS:ICPT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.

Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.

Intercept Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Shiller PE Ratio

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451